NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
TORONTO, June 10, 2019 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (CSE: CHV) (“Canada House” or the “Company”), a fully integrated medical cannabis company, announced today the appointment of two new members of their senior management team, Dr. Lew Pliamm as Medical Director and Liana Del Medico as Director Communications and Investor Relations effective immediately.
The Medical Director is a strategic medical advisor across all Canada House divisions. Dr. Lew Pliamm has practiced Family Medicine for over 25 years in Toronto and is the Lead Physician and Medical Director for the Polyclinic Family and Specialty Medicine Facility as well as the Polyclinic Family Health Group. Dr. Pliamm is also the Principal Investigator and Medical Director of Canadian Phase Onward Inc., a clinical research organization where he has worked for 20 years as a principal investigator on numerous clinical trials for both the pharmaceutical industry and academic institutions. Dr. Pliamm has spoken for several organizations at an international level. In addition to his various clinical leadership roles, Dr. Pliamm has become a recognized expert in medically related real estate, specializing in the development and leasing of medical buildings which will support Canada House Clinic’s “clinic-in-clinic" model.
“We are thrilled to bring Dr. Pliamm on board. His experience in family practice and pharmaceutical industry research can support all of our divisions,” said Chris Churchill-Smith, CEO, Canada House. “Dr. Pliamm’s hire demonstrates our commitment to leadership in cannabinoid therapy and the continued development of leading medical cannabis products.”
“I am very excited to be joining Canada House,” added Dr. Pliamm. “The company is committed to patient care, which is demonstrated by its support in clinics, the strength of the leadership team, and Canada House’s ability, along with its licensed producer, to deliver high quality medical cannabis.”
Mrs. Del Medico will work with the executive team and lead all strategic communications and investor relations activity across Canada House. She has worked in Corporate Communications for over 20 years in various industries including cannabis, pharmaceuticals, and consumer goods. She has an extensive background in media, physician, investor, and consumer communications, organizational change, and mergers and acquisitions. Mrs. Del Medico also brings vast experience working with various organizations in highly regulated environments.
“Finding a leading communications professional with experience in highly regulated environments, specifically pharmaceutical and cannabis, was important for the management team at Canada House,” said Michael Orrbrooke, Chief Revenue Officer, Canada House. “Liana comes with a wealth of experience dealing with media, consumers, investors and regulators. We are thrilled to have her onboard.”
About Canada House Wellness Group Inc.
Canada House Wellness Group Inc. is the parent company of Abba Medix Corp., a Licensed Producer in Pickering, Ontario that produces high quality medical grade cannabis; Canada House Clinics Inc., with clinics across the country that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from complex medical conditions; and Knalysis Technologies, a provider of fully customizable, cloud-based software that links physician, provider, and patient to data that supports treatment with medical cannabis.
Canada House Wellness Group’s goal is to become the leading cultivator of premium craft cannabis and provider of cannabinoid therapy, targeting the medical cannabis markets globally.
For more information please visit www.canadahouse.ca.
For further information, please contact:
Liana Del Medico, Director of Communications & Investor Relations
Canada House Wellness Group Inc.
289-980-3584
liana.delmedico@canadahouse.ca
Cautionary Statement Regarding Forward-Looking Information. This press release contains forward-looking statements, including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
